Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Aileron Therapeutics Announces CEO Transition

Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event

Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024

Aileron Therapeutics Announces Acquisition of Lung Therapeutics

Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives

Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements

Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split

Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conference